Other languages Altimmune, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2024 BST			5-day change	1st Jan Change
8.87 ^USD	+13.43%		+23.88%	-21.16%

05-09	Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09	Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000	MT

Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09
Altimmune Shares Decline After Guggenheim Downgrade	04-29
Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B	03-27
Altimmune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-27
Drugmakers deepen efforts to tap into booming market for obesity drugs	02-27
Zealand shares surge on liver drug data from Boehringer pact	02-26
Altimmune shares slide after Kerrisdale Capital takes short position	02-13
Weight loss drug windfall attracts pharma companies	01-11
Drugmakers plot way into obesity market with deals and development	01-11
USA: 1000 Dollar monatlich für Anti-Adipositas-Behandlung	01-09
Kosten van een obesitasbehandeling in de VS: 1000 USD per maand	01-07
Negli USA, 1.000 dollari al mese per un trattamento anti-obesità	01-04
En EE.UU., 1.000 dólares al mes por un tratamiento contra la obesidad	01-02
Aux USA, 1000 USD par mois pour un traitement anti-obésité	01-02
Social Buzz: Wallstreetbets Stocks Mostly Up Premarket; Altimmune Poised to Rise, Robinhood Markets to Decline	12-07
Altimmune open to partnerships, deals with drugmakers, says CEO	12-05
Roche enters obesity drugs race with $2.7 bln Carmot deal	12-04
Roche enters obesity drugs race with $2.7 bln Carmot deal	12-04
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech	12-01
Top Premarket Gainers	12-01

No results for this search